カテゴリー： Transparency Market Research, 世界, 医療/バイオ

高脂血症治療薬の世界市場2023～2031：治療薬種類別、流通チャネル別

◆英語タイトル：Antihyperlipidemic Drugs Market (Drug Class: Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, and Miscellaneous Antihyperlipidemic Agents) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transparency Market Researchが発行した調査報告書（TMR23MA098）◆商品コード：TMR23MA098
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2023年3月13日
◆ページ数：207
◆レポート形式：英語 / PDF
◆納品方法：Eメール（納期はお問い合わせください。）
◆調査対象地域：北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ
◆産業分野：製薬
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥869,250見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,319,250見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,769,250見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の本市場調査報告書によると、世界の高脂血症治療薬市場規模が、2023年の120億ドルから2031年には201億ドルまでCAGR 6.1%成長すると予測されています。本書は高脂血症治療薬の世界市場について多角的に調査・分析し、序論、仮定、調査方法、エグゼクティブサマリー、市場概要、新型コロナウイルス感染症分析、治療薬種類別（スタチン、胆汁酸捕捉剤、コレステロール吸収阻害剤、フィブリン酸誘導体、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、主要ポイントなどの内容を掲載しています。なお、本書には、AbbVie, Inc.、Amgen, Inc.、AstraZeneca plc、Bristol-Myers Squibb Company、Daiichi Sankyo Company, Limited、Dr. Reddy’s Laboratories Ltd.、Merck & Co., Inc.、Mylan N.V、Pfizer, Inc.、Sanofi S.A.、Esperion Therapeutics、CJ Healthcare、Novartisなどの企業情報が含まれています。
・序論
・仮定
・調査方法
・エグゼクティブサマリー
・市場概要
・新型コロナウイルス感染症分析
・世界の高脂血症治療薬市場規模：治療薬種類別
- スタチンの市場規模
- 胆汁酸捕捉剤の市場規模
- コレステロール吸収阻害剤の市場規模
- フィブリン酸誘導体の市場規模
- その他治療薬種類の市場規模
・世界の高脂血症治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の高脂血症治療薬市場規模：地域別
- 北米の高脂血症治療薬市場規模
- ヨーロッパの高脂血症治療薬市場規模
- アジア太平洋の高脂血症治療薬市場規模
- 中東・アフリカの高脂血症治療薬市場規模
- 中南米の高脂血症治療薬市場規模
・競争状況
・企業情報
・主要ポイント

Antihyperlipidemic Drugs Market – Scope of Report
TMR’s report on the global antihyperlipidemic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global antihyperlipidemic drugs market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global antihyperlipidemic drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the antihyperlipidemic drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global antihyperlipidemic drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global antihyperlipidemic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global antihyperlipidemic drugs market.

The report delves into the competitive landscape of the global antihyperlipidemic drugs market. Key players operating in the global antihyperlipidemic drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global antihyperlipidemic drugs market profiled in this report.

Key Questions Answered in Global Antihyperlipidemic Drugs Market Report
• What is the sales/revenue generated by antihyperlipidemic drugs across all regions during the forecast period?
• What are the opportunities in the global antihyperlipidemic drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Antihyperlipidemic Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global antihyperlipidemic drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global antihyperlipidemic drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global antihyperlipidemic drugs market.

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Antihyperlipidemic Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Drug Class Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Antihyperlipidemic Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Industry Events
    5.3. Regulatory Scenario by Region/Globally
    5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017–2031
        6.3.1. Statins
        6.3.2. Bile Acid Sequestrants
        6.3.3. Cholesterol Absorption Inhibitors
        6.3.4. Fibric Acid Derivatives
        6.3.5. PCSK9 Inhibitors
        6.3.6. Miscellaneous Antihyperlipidemic Agents
    6.4. Market Attractiveness Analysis, by Drug Class
7. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Distribution Channel, 2017–2031
        7.3.1. Hospital Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. Online Pharmacies
    7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness Analysis, by Region
9. North America Antihyperlipidemic Drugs Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Drug Class, 2017–2031
        9.2.1. Statins
        9.2.2. Bile Acid Sequestrants
        9.2.3. Cholesterol Absorption Inhibitors
        9.2.4. Fibric Acid Derivatives
        9.2.5. PCSK9 Inhibitors
        9.2.6. Miscellaneous Antihyperlipidemic Agents
    9.3. Market Value Forecast, by Distribution Channel, 2017–2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Value Forecast, by Country, 2017–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Drug Class
        9.5.2. By Distribution Channel
        9.5.3. By Country
10. Europe Antihyperlipidemic Drugs Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017–2031
        10.2.1. Statins
        10.2.2. Bile Acid Sequestrants
        10.2.3. Cholesterol Absorption Inhibitors
        10.2.4. Fibric Acid Derivatives
        10.2.5. PCSK9 Inhibitors
        10.2.6. Miscellaneous Antihyperlipidemic Agents
    10.3. Market Value Forecast, by Distribution Channel, 2017–2031
        10.3.1. Hospital Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. Online Pharmacies
    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Drug Class
        10.5.2. By Distribution Channel
        10.5.3. By Country/Sub-region
11. Asia Pacific Antihyperlipidemic Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017–2031
        11.2.1. Statins
        11.2.2. Bile Acid Sequestrants
        11.2.3. Cholesterol Absorption Inhibitors
        11.2.4. Fibric Acid Derivatives
        11.2.5. PCSK9 Inhibitors
        11.2.6. Miscellaneous Antihyperlipidemic Agents
    11.3. Market Value Forecast, by Distribution Channel, 2017–2031
        11.3.1. Hospital Pharmacies
        11.3.2. Retail Pharmacies
        11.3.3. Online Pharmacies
    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Drug Class
        11.5.2. By Distribution Channel
        11.5.3. By Country/Sub-region
12. Latin America Antihyperlipidemic Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017–2031
        12.2.1. Statins
        12.2.2. Bile Acid Sequestrants
        12.2.3. Cholesterol Absorption Inhibitors
        12.2.4. Fibric Acid Derivatives
        12.2.5. PCSK9 Inhibitors
        12.2.6. Miscellaneous Antihyperlipidemic Agents
    12.3. Market Value Forecast, by Distribution Channel, 2017–2031
        12.3.1. Hospital Pharmacies
        12.3.2. Retail Pharmacies
        12.3.3. Online Pharmacies
    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Drug Class
        12.5.2. By Distribution Channel
        12.5.3. By Country/Sub-region
13. Middle East & Africa Antihyperlipidemic Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017–2031
        13.2.1. Statins
        13.2.2. Bile Acid Sequestrants
        13.2.3. Cholesterol Absorption Inhibitors
        13.2.4. Fibric Acid Derivatives
        13.2.5. PCSK9 Inhibitors
        13.2.6. Miscellaneous Antihyperlipidemic Agents
    13.3. Market Value Forecast, by Distribution Channel, 2017–2031
        13.3.1. Hospital Pharmacies
        13.3.2. Retail Pharmacies
        13.3.3. Online Pharmacies
    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Drug Class
        13.5.2. By Distribution Channel
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player – Competition Matrix (by tier and size of companies)
    14.2. Market Share Analysis, by Company, 2021
    14.3. Company Profiles
        14.3.1. AbbVie, Inc.
            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.1.2. Product Portfolio
            14.3.1.3. Financial Overview
            14.3.1.4. SWOT Analysis
            14.3.1.5. Strategic Overview
        14.3.2. Amgen, Inc.
            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.2.2. Product Portfolio
            14.3.2.3. Financial Overview
            14.3.2.4. SWOT Analysis
            14.3.2.5. Strategic Overview
        14.3.3. AstraZeneca plc
            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.3.2. Product Portfolio
            14.3.3.3. Financial Overview
            14.3.3.4. SWOT Analysis
            14.3.3.5. Strategic Overview
        14.3.4. Bristol-Myers Squibb Company
            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.4.2. Product Portfolio
            14.3.4.3. Financial Overview
            14.3.4.4. SWOT Analysis
            14.3.4.5. Strategic Overview
        14.3.5. Daiichi Sankyo Company Limited
            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.5.2. Product Portfolio
            14.3.5.3. Financial Overview
            14.3.5.4. SWOT Analysis
            14.3.5.5. Strategic Overview
        14.3.6. Dr. Reddy’s Laboratories Ltd.
            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.6.2. Product Portfolio
            14.3.6.3. Financial Overview
            14.3.6.4. SWOT Analysis
            14.3.6.5. Strategic Overview
        14.3.7. Merck & Co., Inc.
            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.7.2. Product Portfolio
            14.3.7.3. Financial Overview
            14.3.7.4. SWOT Analysis
            14.3.7.5. Strategic Overview
        14.3.8. Mylan N.V
            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.8.2. Product Portfolio
            14.3.8.3. Financial Overview
            14.3.8.4. SWOT Analysis
            14.3.8.5. Strategic Overview
        14.3.9. Pfizer, Inc.
            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.9.2. Product Portfolio
            14.3.9.3. Financial Overview
            14.3.9.4. SWOT Analysis
            14.3.9.5. Strategic Overview
        14.3.10. Sanofi S.A.
            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.10.2. Product Portfolio
            14.3.10.3. Financial Overview
            14.3.10.4. SWOT Analysis
            14.3.10.5. Strategic Overview
        14.3.11. Esperion Therapeutics
            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.11.2. Product Portfolio
            14.3.11.3. Financial Overview
            14.3.11.4. SWOT Analysis
            14.3.11.5. Strategic Overview
        14.3.12. CJ Healthcare
            14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.12.2. Product Portfolio
            14.3.12.3. Financial Overview
            14.3.12.4. SWOT Analysis
            14.3.12.5. Strategic Overview
        14.3.13. Novartis
            14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.13.2. Product Portfolio
            14.3.13.3. Financial Overview
            14.3.13.4. SWOT Analysis
            14.3.13.5. Strategic Overview

List of Tables

Table 01: Global Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 05: North America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: North America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: Europe Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 08: Europe Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Asia Pacific Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Asia Pacific Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: Asia Pacific Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Latin America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 14: Latin America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 15: Latin America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Middle East & Africa Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 17: Middle East & Africa Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 18: Middle East & Africa Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 高脂血症治療薬の世界市場2023～2031：治療薬種類別、流通チャネル別(Antihyperlipidemic Drugs Market (Drug Class: Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, and Miscellaneous Antihyperlipidemic Agents) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界の頭頸部がん市場2023-2031：薬剤クラス別（EFGR阻害剤、分裂阻害剤、抗PD-1モノクローナル抗体、その他）、流通チャネル別（病院薬局、小売薬局、Eコマース）
  • 世界のアルツハイマー病に伴う認知症市場2023-2031：薬剤クラス別（コリン作動性/コリンエステラーゼ阻害薬、メマンチン、配合剤、その他）、流通チャネル別（病院薬局、小売店、オンライン販売）
  • 多発性硬化症治療の世界市場2022～2031：治療薬別、流通チャネル別
  • 世界の増殖糖尿病網膜症市場2023-2031：薬剤クラス別（抗VEGF薬、副腎皮質ステロイド薬）、投与形態別（注射剤、経口剤、その他）
  • RAS作用薬の世界市場2023～2031：薬物クラス別

    • ◆H&Iグローバルリサーチのお客様（例）◆